RT @MrDoctorOficial: De hecho, en personas que disminuyen 15kg podrían remitir la diabetes. https://t.co/YfJgDJ3qwF https://t.co/OOgewS3OOK
De hecho, en personas que disminuyen 15kg podrían remitir la diabetes. https://t.co/YfJgDJ3qwF https://t.co/OOgewS3OOK
RT @DrGiovanniD: Aquí dejo las GPC https://t.co/ajpQh3pyCT
Aquí dejo las GPC https://t.co/ajpQh3pyCT
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
RT @DrGiovanniD: 86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes…
86% de los pacientes con nuevo diagnóstico de diabetes tipo 2 que pierden 15 kg experimentan reversibilidad de la diabetes (remisión). Es decir tienen niveles adecuados de glucosa sin necesidad de fármacos, su celula B vuelve a producir insulina. Guías.👉ht
Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) | SpringerLink https://t.co/oG3OV1Nltx
現在利用可能なGLP-1受容体作動薬は全て皮下注射投与です。1日1回のリラグルチドはHbA1cと体重減少効果が、週1回のセマグルチドは同クラス薬よりも優れたHbA1cおよび体重減少効果が報告されており、2剤とも2型糖尿病患者の心血管系疾患抑制目的の使用が推奨されています。 https://t.co/hc6CN4grmM
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ…
Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #NephJC 👉🏼 https://t.co/tP3NduZZ6L https://t.co/64Dn4A7erd
RT @ClinMedJournals: Top-downloaded content in Springer’s Internal Medicine portfolio. Management of hyperglycaemia in type 2 diabetes, 201…
RT @ClinMedJournals: Top-downloaded content in Springer’s Internal Medicine portfolio. Management of hyperglycaemia in type 2 diabetes, 201…
RT @ClinMedJournals: Top-downloaded content in Springer’s Internal Medicine portfolio. Management of hyperglycaemia in type 2 diabetes, 201…
RT @ClinMedJournals: Top-downloaded content in Springer’s Internal Medicine portfolio. Management of hyperglycaemia in type 2 diabetes, 201…
Top-downloaded content in Springer’s Internal Medicine portfolio. Management of hyperglycaemia in type 2 diabetes, 2018: A consensus report by the ADA and EASD, from @DiabetologiaJnl https://t.co/16szEIUAax https://t.co/kMAbOcLEDH
RT @edgarvlermamd: Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https…
RT @edgarvlermamd: Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https…
@agargmd @usambcuba @GDirlam @KoushikReddyMD @jlevallois @EAllen0417 @SteveLome @drjkahn @Veg_MD @vegannutrition1 @virtahealth Here are guidelines from ADA/EASD that include carbohydrate restriction at <26% calories as one of the recommended patterns of
@tarosuke104 こちらをどうぞ https://t.co/Tnjq5j9fQH
Consenso de Diabetes https://t.co/SWZzltIQ6t
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @juanmarcosgg: , consenso de la sociedad americana y europea de diabetes en el tratamiento de la diabetes tipo 2 https://t.co/w8Vl1iJuDe)
, consenso de la sociedad americana y europea de diabetes en el tratamiento de la diabetes tipo 2 https://t.co/w8Vl1iJuDe)
RT @janespeight: All working in #type2diabetes care need to be aware of NEW consensus guidelines on managing hyperglycaemia from @AmDiabete…
RT @janespeight: All working in #type2diabetes care need to be aware of NEW consensus guidelines on managing hyperglycaemia from @AmDiabete…
RT @janespeight: All working in #type2diabetes care need to be aware of NEW consensus guidelines on managing hyperglycaemia from @AmDiabete…
RT @janespeight: All working in #type2diabetes care need to be aware of NEW consensus guidelines on managing hyperglycaemia from @AmDiabete…
All working in #type2diabetes care need to be aware of NEW consensus guidelines on managing hyperglycaemia from @AmDiabetesAssn & @EASDnews says A/Prof Mark Kennedy @PCDSAus #pcdsa https://t.co/RgfHxFB3bp https://t.co/ZliWcs8LV3
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https:…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https:…
RT @edgarvlermamd: Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https:…
RT @edgarvlermamd: PANENI: Decision cycle for patient-centered glycemic management in Type 2 Diabetes #Nephpearls #Cardiorenal #AHA18 🇺🇸…
RT @edgarvlermamd: PANENI: Decision cycle for patient-centered glycemic management in Type 2 Diabetes #Nephpearls #Cardiorenal #AHA18 🇺🇸…
Choosing glucose lowering medication in those w/ established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/tP3NdvhAvl https://t.co/Y6MSBkx3DJ
Geen verassend nieuws. De Nederlandse diabetesbehandelaar doet er goed aan de recent vernieuwde EASD guideline te raadplegen @DiabetologiaJnl @EASDnews. https://t.co/yccjmKs69q
RT @profsmarshall: Up front & free to read in @DiabetologiaJnl Dec issue: Management of hyperglycaemia in type 2 diabetes, 2018. A consensu…
このコンセンサスレポートは読むとお得な感じで、 現時点でエビデンスに基づいた最高レベルの臨床での見解が示されている 何回読んでみても面白いレベルです
Management of hyperglycaemia in #type2diabetes, 2018. A consensus report by the American Diabetes Association (#ADA) and the European Association for the Study of Diabetes (#EASD). @DiabetologiaJnl https://t.co/7EfMvQvgSg
RT @edgarvlermamd: Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https…
RT @edgarvlermamd: Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https…
RT @edgarvlermamd: PANENI: Decision cycle for patient-centered glycemic management in Type 2 Diabetes #Nephpearls #Cardiorenal #AHA18 🇺🇸…
RT @edgarvlermamd: Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https…
Glucose lowering medications in Type 2 Diabetes: Established ASCVD or CKD #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/ZqqvqpZeWt
PANENI: Decision cycle for patient-centered glycemic management in Type 2 Diabetes #Nephpearls #Cardiorenal #AHA18 🇺🇸 👉🏼 https://t.co/E11n7xQkjL https://t.co/Pg7eniFX7a
RT @profsmarshall: Up front & free to read in @DiabetologiaJnl Dec issue: Management of hyperglycaemia in type 2 diabetes, 2018. A consensu…
RT @profsmarshall: Up front & free to read in @DiabetologiaJnl Dec issue: Management of hyperglycaemia in type 2 diabetes, 2018. A consensu…
RT @profsmarshall: Up front & free to read in @DiabetologiaJnl Dec issue: Management of hyperglycaemia in type 2 diabetes, 2018. A consensu…
RT @profsmarshall: Up front & free to read in @DiabetologiaJnl Dec issue: Management of hyperglycaemia in type 2 diabetes, 2018. A consensu…
RT @profsmarshall: Up front & free to read in @DiabetologiaJnl Dec issue: Management of hyperglycaemia in type 2 diabetes, 2018. A consensu…
Up front & free to read in @DiabetologiaJnl Dec issue: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) https://t.co/7iWXk
New EASD-ADA guidelines for #diabetes therapy put the patient at the center of the treatment decision https://t.co/cuX3RZC3gQ https://t.co/jdLvhFuSXg
RT @DrAbdulWPhD: #GPPharmacists management of #Type2diabetes ADA statement 2018 - check it 👇 https://t.co/izOKizG1D9 https://t.co/4gIJtHiYIY
#GPPharmacists management of #Type2diabetes ADA statement 2018 - check it 👇 https://t.co/izOKizG1D9 https://t.co/4gIJtHiYIY
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
RT @IlindelatorreMD: Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association fo…
Manejo de la hiperglucemia en la diabetes tipo 2, 2018 | American Diabetes Association (ADA) y European Association for the Study of Diabetes (EASD) https://t.co/VBKLGY8M3k https://t.co/NrgGlFEyvi